New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration

NDA FilingLAE002Positive

AI Analysis

Summary

Laekna announced that its New Drug Application for LAE002 (afuresertib) has been accepted by China's National Medical Products Administration for evaluation. This represents a regulatory milestone in the development of the drug for treating patients with an unspecified indication.

Outcome Details

New Drug Application accepted by China's NMPA Center for Drug Evaluation

Importance:6/10

Sentiment:

0.70

ChinaNMPAregulatoryNDA acceptance

Related Companies

$NHPAP $MDCE $CHHE

Read the original article

Published by PR Newswire Pharma on August 12, 2026 12:45 AM

Read Original